B-cell Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for B-cell Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease [Phase 2]
Phase 2 trial assessing blinatumomab in adults with B-cell acute lymphoblastic leukemia in complete remission who have minimal residual dise…
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL [Phase 1]
This clinical trial update covers a Phase 1 study evaluating myeloablative conditioning with Orca-T plus donor-derived CD19/CD22-CAR T cells…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) [Phase 2]
A Phase 2 trial evaluating Blinatumomab alone versus Blinatumomab with Nivolumab in patients with first-relapse B-cell acute lymphoblastic l…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) [Phase 1, Phase 2]
Phase 1/2 clinical trial update for UCART22 evaluating safety and early activity in relapsed or refractory CD22-positive B-cell acute lympho…
-
CLINICAL_TRIALS trial_result · 2025-08-26Clinical Trial Update: CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia [Phase 1]
Phase 1 trial of CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia has com…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol [Phase 2, Phase 3]
A newly diagnosed, low-risk pediatric B-cell acute lymphoblastic leukemia protocol is described for Phase 2 and Phase 3 testing and is curre…
-
CLINICAL_TRIALS trial_result · 2025-08-13Clinical Trial Update: RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial update for RN1201 injection in relapsed/refractory CD19+/BCMA+ hematologic malignancies, currently not recruiting.
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) [Phase 1, Phase 2]
A pediatric clinical trial evaluating CNCT19, a CAR-T therapy, for relapsed/refractory B-cell acute lymphoblastic leukemia in children and a…
-
CLINICAL_TRIALS withdrawal · 2025-08-08Clinical Trial Update: A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating HY004 for adult relapsed/refractory B-cell Acute Lymphoblastic Leukemia has been withdrawn.
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). [Phase 1, Phase 2]
This Clinical Trial Update describes a fourth-generation CD19/CD22 dual-targeting CAR T-cell therapy being evaluated in Phase 1/2 for highly…
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies [Phase 1]
A Phase 1 trial evaluating CD180 CAR-T therapy for relapsed or refractory CD180-positive hematologic malignancies is currently recruiting, i…
-
CLINICAL_TRIALS research · 2025-07-23Clinical Trial Update: A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL [Phase 1]
Phase 1 study evaluating FIT-CD19-CAR-T Cells for relapsed/refractory B-cell acute lymphoblastic leukemia is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-07-17Clinical Trial Update: Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies [Phase 2]
Phase 2 clinical trial update evaluating a bridging regimen containing mitoxantrone hydrochloride liposome injection together with CD19-targ…
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia [NA]
A clinical trial update for JY231 injection in relapsed or refractory B-cell lymphomas and leukemias, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-06-29Clinical Trial Update: Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies [Phase 1]
Phase 1 study evaluating CD19/CD22 CAR-T cells in children and young adults with recurrent or refractory B-cell acute lymphoblastic leukemia…
-
CLINICAL_TRIALS research · 2025-06-29Clinical Trial Update: A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia [Phase 1]
A Phase 1 clinical study evaluating universal CAR-T cells in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, which is…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL) [NA]
Clinical trial update for a nutrition and exercise program in adults undergoing treatment for acute lymphoblastic leukemia (ALL); the study …
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Pre-emptive Anakinra for Cytokine Event Reduction [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating pre-emptive anakinra to reduce cytokine release syndrome and related neurotoxicity in CAR-T cell therapy…
-
CLINICAL_TRIALS research · 2025-06-10Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia [NA]
This clinical trial update indicates that JY231 injection is being studied for relapsed/refractory B-cell acute lymphoblastic leukemia and B…
-
CLINICAL_TRIALS trial_result · 2025-06-05Clinical Trial Update: T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia [Phase 1]
This clinical trial update describes a Phase 1 study evaluating autologous CD19-targeted CAR-T cells in pediatric and young adult patients w…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL [Phase 2]
This Phase 2 clinical trial investigates a consolidation strategy using CD22/CD19 CAR-T cells followed by autologous hematopoietic stem cell…
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies [Phase 1]
Phase 1 study evaluating CD19/CD22 CAR T cells in children and young adults with recurrent or refractory CD19/CD22-expressing B cell maligna…
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) [EARLY_Phase 1]
This early-phase 1 trial investigates a dual-targeting CD19-CD22 CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic le…
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia [Phase 1]
A Phase 1 trial of a triple-targeted CD19/CD20/CD22 CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia has been …
-
CLINICAL_TRIALS research · 2025-05-29Clinical Trial Update: The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells
This clinical trial explores how CD19 expression across primitive cellular fractions in relapsed B-cell acute lymphoblastic leukemia affects…